

**Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7)  
Recombinant Antibody  
Catalog # APR10914****Specification**

---

**Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">O75084</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	150 KDa

**Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) - Additional Information****Target/Specificity**  
FZD7**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) - Protein Information****Name** FZD7**Function**  
Receptor for Wnt proteins. Most frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. Activation by WNT8 induces expression of beta-catenin target genes (By similarity). Following ligand activation, binds to CCDC88C/DAPLE which displaces DVL1 from FZD7 and leads to inhibition of canonical Wnt signaling, activation of G-proteins by CCDC88C and triggering of non-canonical Wnt responses (PubMed:<a href="http://www.uniprot.org/citations/26126266" target="\_blank">26126266</a>). May be involved in transduction and intercellular transmission of polarity information during tissue

morphogenesis and/or in differentiated tissues.

#### Cellular Location

Cell membrane; Multi-pass membrane protein. Endosome membrane; Multi-pass membrane protein. Note=Associated to the plasma membrane in the presence of FZD7 and phosphatidylinositol 4,5-bisphosphate (PIP2). Localized in recycling endosomes in other conditions

#### Tissue Location


High expression in adult skeletal muscle and fetal kidney, followed by fetal lung, adult heart, brain, and placenta Specifically expressed in squamous cell esophageal carcinomas

### Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) - Images



Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) is more than 95%, determined by SEC-HPLC.